Published in Clin Infect Dis on November 05, 2010
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ (2011) 1.61
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2016) 1.58
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob Agents Chemother (2012) 1.09
Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis (2013) 0.95
Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production. Infect Immun (2013) 0.93
A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother (2013) 0.89
Clinical implications of interferon-γ genetic and epigenetic variants. Immunology (2014) 0.85
Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis (2012) 0.84
Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. J Immunol (2014) 0.81
Evaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis. J Clin Microbiol (2011) 0.80
Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung (2011) 0.80
Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection. Clin Infect Dis (2010) 0.79
The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. Antimicrob Agents Chemother (2015) 0.77
Iatrogenic Cushing's syndrome induced by posaconazole. Antimicrob Agents Chemother (2013) 0.76
Late post-operative Aspergillus flavus endocarditis: Demonstration of a six years incubation period using microsatellite typing. Med Mycol Case Rep (2012) 0.75
Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole. Transpl Infect Dis (2015) 0.75
[Aspergillus in airway material : Ignore or treat?] Internist (Berl) (2017) 0.75
Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria. Eur J Clin Microbiol Infect Dis (2013) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature (2005) 7.74
Hidden killers: human fungal infections. Sci Transl Med (2012) 7.10
Genome sequencing and analysis of Aspergillus oryzae. Nature (2005) 5.47
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis (2009) 4.71
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ (2008) 3.32
Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. PLoS Genet (2008) 3.23
Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine (2006) 3.18
Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2010) 3.15
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys (2011) 2.86
Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol (2012) 2.68
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat (2009) 2.63
Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials (2005) 2.62
Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc (2010) 2.59
Adverse reactions to voriconazole. Clin Infect Dis (2004) 2.51
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis (2003) 2.49
Tackling human fungal infections. Science (2012) 2.49
Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents (2006) 2.30
Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother (2011) 2.27
Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J Clin Microbiol (2003) 2.18
Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. Curr Biol (2005) 2.12
Comparison of generic versus specific quality-of-life scales for mesh hernia repairs. J Am Coll Surg (2008) 2.07
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother (2010) 2.03
Therapy for fungal diseases: opportunities and priorities. Trends Microbiol (2010) 1.95
Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol (2003) 1.90
Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab (2008) 1.86
Female genital injuries resulting from consensual and non-consensual vaginal intercourse. Forensic Sci Int (2010) 1.85
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int (2013) 1.84
The eighty-hour workweek: surgical attendings' perspectives. J Surg Educ (2010) 1.83
Comparison of blood vessel sealing among new electrosurgical and ultrasonic devices. Surg Endosc (2008) 1.81
Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod (2012) 1.78
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis (2011) 1.72
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother (2006) 1.71
Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma (2012) 1.67
Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol (2002) 1.66
Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol (2006) 1.65
Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril (2008) 1.64
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2013) 1.63
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother (2005) 1.61
Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope (2009) 1.54
Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab (2010) 1.54
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest (2013) 1.46
Elective single embryo transfer: guidelines for practice British Fertility Society and Association of Clinical Embryologists. Hum Fertil (Camb) (2008) 1.46
A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health (2007) 1.44
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis (2003) 1.44
A cautionary tale: Lack of consistency in allele sizes between two laboratories for a published multilocus microsatellite typing system. J Clin Microbiol (2006) 1.43
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother (2011) 1.41
Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother (2009) 1.41
Bursting strength evaluation in an experimental model of incisional hernia. Am Surg (2008) 1.39
Informing adolescents about human papillomavirus vaccination: what will parents allow? Vaccine (2008) 1.37
Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med (2005) 1.37
Hepatic tumor ablation with clustered microwave antennae: the US Phase II trial. HPB (Oxford) (2007) 1.33
Insight into the genome of Aspergillus fumigatus: analysis of a 922 kb region encompassing the nitrate assimilation gene cluster. Fungal Genet Biol (2004) 1.33
Initial laparoscopic basic skills training shortens the learning curve of laparoscopic suturing and is cost-effective. J Am Coll Surg (2010) 1.30
The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother (2013) 1.29
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res (2008) 1.28
Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis (2008) 1.27
Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res (2004) 1.27
Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol (2006) 1.25
Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother (2004) 1.25
Technique and outcomes of abdominal incisional hernia repair using a synthetic composite mesh: a report of 455 cases. J Am Coll Surg (2007) 1.25
Delivery of chlamydia screening to young women requesting emergency hormonal contraception at pharmacies in Manchester, UK: a prospective study. BMC Womens Health (2009) 1.21
Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence. Eukaryot Cell (2004) 1.17
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis (2011) 1.17
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother (2004) 1.16
Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med (2006) 1.16
Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother (2008) 1.16
Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax (2011) 1.15
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents (2010) 1.14
Tissue penetration of antifungal agents. Clin Microbiol Rev (2014) 1.13
Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother (2009) 1.11
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob Agents Chemother (2006) 1.11
Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences. Value Health (2011) 1.10
Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol (2006) 1.10
Evidence for recombination in Candida glabrata. Fungal Genet Biol (2005) 1.10
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother (2013) 1.09
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
Candida tropicalis in human disease. Crit Rev Microbiol (2010) 1.08
Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol (2011) 1.08
Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus. Med Mycol (2005) 1.07
The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod (2009) 1.07
EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses (2014) 1.05
Aspergillus genomes and the Aspergillus cloud. Nucleic Acids Res (2008) 1.05